Shah Paras P, Gelnick Samuel, Zhu Daniel, Wong Amanda, Verma Rashmi
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA.
Department of Ophthalmology, Northwell Health, Great Neck, NY, USA.
Oman J Ophthalmol. 2022 Aug 3;15(3):397-402. doi: 10.4103/ojo.ojo_354_21. eCollection 2022 Sep-Dec.
The COVID‑19 pandemic has had a significant public health impact globally, with inoculation now paramount in limiting the spread of the disease. Although the safety and efficacy profiles of COVID‑19 vaccines are well documented, it is upon the medical community to be aware of adverse effects to appropriately advise and treat patients. We report the case of a 39‑year‑old female who was hospitalized with optic neuritis (ON) 1 week after her second dose of the Pfizer‑BioNTech (BNT162b2) COVID‑19 vaccine. The patient did not have any significant medical history, including personal or familial history of multiple sclerosis or any other demyelinating disease, other than prior COVID‑19 infection. She had since made a full recovery and tested negative at the time of hospitalization for ON. Over the course of her admission, the patient's visual acuity (VA) deteriorated from 20/400 to no light perception. After methylprednisolone was ineffective, she was started on plasmapheresis (PLEX) therapy which resulted in mild improvement of VA. To our knowledge and after a thorough PubMed literature search, this is the first reported case of isolated ON associated with COVID‑19 vaccination.
新冠疫情对全球公共卫生产生了重大影响，目前接种疫苗对于限制疾病传播至关重要。尽管新冠疫苗的安全性和有效性已有充分记录，但医学界有责任了解不良反应，以便为患者提供适当的建议和治疗。我们报告了一例39岁女性病例，她在接种第二剂辉瑞-生物科技公司（BNT162b2）新冠疫苗1周后因视神经炎（ON）住院。该患者没有任何重大病史，包括个人或家族性多发性硬化症或任何其他脱髓鞘疾病病史，仅有既往新冠病毒感染史。她此后已完全康复，住院时视神经炎检测呈阴性。在住院期间，患者的视力（VA）从20/400恶化为无光感。甲基泼尼松龙治疗无效后，她开始接受血浆置换（PLEX）治疗，视力有轻度改善。据我们所知，经过全面的PubMed文献检索，这是首例报告的与新冠疫苗接种相关的孤立性视神经炎病例。
